Grape King BioTPE:1707 -0.11%78 EV-to-FCF is 6.49 as of Jul. 08, 2026, which is 55% below its 10-year median of 14.41. GuruFocus rates TPE:1707 with a GF Score™ of 78/100 and a GF Value™ of NT$144.03 (Possible Value Trap). The stock has 5 warning signs investors should review. Among 563 Drug Manufacturers companies, Grape King Bio ranks better than 85.26% on this metric.
EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Grape King Bio's Enterprise Value is NT$11,142 Mil.
Grape King Bio's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2025 was NT$1,716 Mil. Therefore, Grape King Bio's EV-to-FCF for today is 6.49.
The historical rank and industry rank for Grape King Bio's EV-to-FCF or its related term are showing as below:
TPE:1707'
s EV-to-FCF Range Over the Past 10 Years
Min: 5.94 Med: 14.41 Max: 44.2
Current: 6.66
During the past 13 years, the highest EV-to-FCF of Grape King Bio was 44.20. The lowest was 5.94. And the median was 14.41.
TPE:1707's EV-to-FCF is ranked better than 85.26% of 563
companies
in the Drug Manufacturers industry
Industry Median: 20.85
vs TPE:1707: 6.66
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Grape King Bio's PE Ratio (TTM) for today is calculated as:
Grape King Bio's share price for today is NT$91.00.
Grape King Bio's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was NT$8.180.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Grape King Bio EV-to-FCF Related Terms
Grape King Bio EV-to-FCF Historical Data
* Premium members only.
The historical data trend for Grape King Bio's EV-to-FCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Grape King Bio's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Grape King Bio EV-to-FCF vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Grape King Bio's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where Grape King Bio's EV-to-FCF falls into.
Grape King Bio's current Enterprise Value is NT$11,142 Mil.
Grape King Bio's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was NT$1,716 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Grape King Bio (TPE:1707) has a EV-to-FCF of 6.49 as of Jul. 08, 2026. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Grape King Bio and its competitors. This is 55% below median its historical median of 14.41. Over the past decade, Grape King Bio's EV-to-FCF has ranged from 5.94 to 44.20. According to the industry distribution chart, Grape King Bio ranks #83 out of 563 companies in the Drug Manufacturers industry, placing it in the top 14.7%.
Is Grape King Bio's EV-to-FCF too high?
Grape King Bio's current EV-to-FCF of 6.49 is 55% below median its 10-year median of 14.41. Over the past 10 years, this metric has ranged from a low of 5.94 to a high of 44.20. The Drug Manufacturers industry median EV-to-FCF is 20.85. Grape King Bio's value of 6.49 is 68.9% below this industry median. Based on the distribution chart, Grape King Bio ranks #83 out of 563 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Grape King Bio has a GF Score™ of 78/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Grape King Bio's EV-to-FCF compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Grape King Bio ranks #83 out of 563 companies for EV-to-FCF. This places Grape King Bio in the top 15% of its industry — outperforming the majority of peers. The industry median EV-to-FCF is 20.85. Grape King Bio's value of 6.49 is 68.9% below this benchmark. Historically, Grape King Bio's own EV-to-FCF has ranged from 5.94 to 44.20 over the past decade. While the company's 10-year median is 14.41 vs. the industry median of 20.85, Grape King Bio has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-FCF for a Drug Manufacturers company?
The median EV-to-FCF among Drug Manufacturers companies is 20.85, based on 563 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-FCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Grape King Bio's current EV-to-FCF of 6.49 is 68.9% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-FCF mean?
A high EV-to-FCF can signal that a stock is expensive relative to its fundamentals. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Grape King Bio and its competitors. For the Drug Manufacturers industry, the median EV-to-FCF is 20.85 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Grape King Bio's current EV-to-FCF is 6.49, which is 55% below median its own 10-year median of 14.41. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Grape King Bio stock overvalued right now?
Based on GuruFocus' analysis, Grape King Bio (TPE:1707) is currently considered Possible Value Trap. The stock's GF Value™ is NT$144.03, compared to a current price of NT$91.00 — trading 36.8% below its estimated fair value. The current EV-to-FCF is 6.49, which is 55% below median its 10-year median of 14.41 and 68.9% below the Drug Manufacturers industry median of 20.85. Grape King Bio's overall GF Score™ is 78/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-FCF calculated?
EV-to-FCF is calculated from a company's financial statements. For Grape King Bio (TPE:1707), the current EV-to-FCF is 6.49 as of Jul. 08, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Grape King Bio (TPE:1707) Overvalued in 2026?
Based on GuruFocus' analysis, Grape King Bio stock appears to be undervalued.
The current stock price of NT$91.00 is trading 36.8% below its estimated GF Value™ of NT$144.03.
GuruFocus considers Grape King Bio to be Possible Value Trap.
Key valuation signals for TPE:1707:
EV-to-FCF: 6.49 (55% below median its 10-year median of 14.41)
GF Value™: NT$144.03 vs. price of NT$91.00 (36.8% below fair value)
Industry Position: 68.9% below the Drug Manufacturers median (#83 of 563)
No single metric tells the full story. See the TPE:1707 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Grape King Bio Ltd is a specialty and generic drug manufacturing company engaged in producing and selling pharmaceutical preparations, patent medicines, liquid tonics, drinks, and healthy food. The company has three segments: MLM (Multi-Level Marketing), which is a direct seller of Pro-partner Inc, including the company's development and manufacturing products for Pro-partner Inc, the Distributors segment includes the company's self-owned brand products, and ODM/OEM (Original Design Manufacturer/Original Equipment Manufacturer) includes ODM/OEM in Taiwan and Shanghai. The group operates in three principal geographical areas - Taiwan, China, and Others, and it derives a majority of its revenue from Taiwan.
78GF Score
Get the complete analysis for TPE:1707
EV-to-FCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TPE:1707 has been successfully added to your 
